Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACSS2 | Q9NR19 | 6/20 | 0.40 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.34 |
| ▸ | METAP2 | P50579 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15060784 | 0.85 | PDE5A (0.37) | ACSS2MAPK14KDM4EMEN1TSHR | |
| SCHEMBL15060785 | 0.83 | METAP2 (0.44) | ACSS2CYP11B2CYP11B1MAPK14METAP2 | |
| SCHEMBL10642457 | 0.80 | RPS6KA5 (0.49) | CYP11B2CYP11B1KDM4EKMT2AMAPT | |
| SCHEMBL12210495 | 0.75 | KDM4E (0.38) | HCRTR1HCRTR2MAPK14KDM4EKMT2A | |
| SCHEMBL13273928 | 0.74 | HSP90AA1 (0.37) | MAPK14KDM4EMAPT | |
| SCHEMBL15061690 | 0.73 | PDE5A (0.35) | MAPK14KDM4EMEN1KMT2AL3MBTL1 | |
| SCHEMBL18404505 | 0.72 | POLB (0.35) | MAPK14KDM4EMAPT | |
| SCHEMBL2492548 | 0.72 | HDAC8 (0.45) | ACSS2HCRTR1HCRTR2 | |
| SCHEMBL7473048 | 0.71 | KDM4E (0.50) | KDM4EMEN1TSHRKMT2AMAPT | |
| SCHEMBL15060824 | 0.71 | F2 (0.39) | ACSS2HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130303535-A1 | NOVEL BICYCLIC HETEROCYCLIC COMPOUND | Sumitomo Pharma Co., Ltd. (JP) | 2013-11-14 | — | — | US | disclosed |
| US-20130303535-A1 | NOVEL BICYCLIC HETEROCYCLIC COMPOUND | Sumitomo Pharma Co., Ltd. (JP) | 2013-11-14 | — | — | US | disclosed |
| US-8471038-B2 | Bicyclic heterocyclic compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2013-06-25 | — | — | US | disclosed |
| US-8471038-B2 | Bicyclic heterocyclic compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2013-06-25 | — | — | US | disclosed |
| US-20110294804-A1 | NOVEL BICYCLIC HETEROCYCLIC COMPOUND | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-12-01 | — | — | US | disclosed |
| US-20110294804-A1 | NOVEL BICYCLIC HETEROCYCLIC COMPOUND | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294804-A1 | NOVEL BICYCLIC HETEROCYCLIC COMPOUND | OPRL1, SCN1B, OPRD1 | ACSS2 2619/4885HCRTR1 34/4885HCRTR2 121/4885 |
| US-20130303535-A1 | NOVEL BICYCLIC HETEROCYCLIC COMPOUND | OPRL1, SCN1B, OPRD1 | ACSS2 2619/4885HCRTR1 34/4885HCRTR2 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.